Sputum high mobility group box-1 in asthmatic children: a noninvasive sensitive biomarker reflecting disease status

Abstract Background The monitoring of asthma is based mainly on clinical history, physical examination, and lung function test evaluation. To improve knowledge of the disease, new biomarkers of airway inflammation, including high mobility group box-1 (HMGB1), are being developed. Objective To evaluate sputum HMGB1 levels in children with stable, off-therapy, allergic asthma and to evaluate the relation between HMGB1 levels and lung function parameters. Methods Fifty children with asthma (28 boys and 22 girls, median age 11.56 ± 1.41 years) and 44 healthy children (22 boys and 22 girls, median age 11.07 ± 2.12 years) were enrolled. Sputum HMGB1 was assessed in the cohort study. Lung function (predicted percentage of forced expiratory volume in 1 second [FEV1 %] and forced expiratory flow between 25% and 75% [FEF25%–75% ]), serum total IgE levels, and asthma severity by validated Global Initiative for Asthma criteria were recorded. Results Sputum HMGB1 levels were higher in children with asthma than in healthy controls (100.68 ± 10.03 vs 9.60 ± 3.76 ng/mL, P < .0001). Sputum HMGB1 levels also were positively related to total IgE levels in children with asthma ( r = 0.6567, P < .0001). An inverse and strict correlation between sputum HMGB1 levels and pulmonary function indices also were observed in children with mild (FEV1 %, r = −0.86544, P < .0001; FEF25%–75% , r = −0.53948, P < .05), moderate (FEV1 %, r = −0.99548, P < .0001; FEF25%–75% , r = −0.48668, P